Feroz Abubacker Kaniyamparambil, MD
Nephrology · Newark, DENPI 1710119045
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations.
Across 152 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$465
- Vifor Pharma, Inc.$348
- Mallinckrodt Hospital Products Inc.$279
- Otsuka America Pharmaceutical, Inc.$259
- Amgen$241
- AstraZeneca$236
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,91694%
- Education$2026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 24 | $465 |
| Vifor Pharma, Inc. | 16 | $348 |
| Mallinckrodt Hospital Products Inc. | 9 | $279 |
| Otsuka America Pharmaceutical, Inc. | 11 | $259 |
| Amgen(2 entities) | 13 | $241 |
| AstraZeneca(2 entities) | 10 | $236 |
| Calliditas Therapeutics US Inc. | 7 | $158 |
| Bayer | 7 | $122 |
| Ardelyx, Inc. | 5 | $106 |
| Akebia Therapeutics Inc | 4 | $97 |
| Daiichi Sankyo Inc. | 5 | $92 |
| Boehringer Ingelheim | 6 | $86 |
| GSK | 5 | $79 |
| Novartis | 2 | $75 |
| Aurinia Pharma U.S., Inc. | 3 | $69 |
| AMAG Pharmaceuticals, Inc. | 4 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| OPKO Pharmaceuticals, LLC | 4 | $52 |
| Travere Therapeutics, Inc. | 3 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| Novo Nordisk | 2 | $36 |
| Astellas Pharma US Inc | 1 | $25 |
| Shire North American Group Inc | 1 | $21 |
| Nxstage Medical, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Sanofi | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
| Daxor Corporation | 1 | $10 |
How this compares
$3,119 in reported general payments places this provider in the 60th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 25 | $22,658 |
| KerendiaFinerenone | 19 | $18,992 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $4,603 |
| Potassium Citrate ErPotassium Citrate | 24 | $3,340 |
| Losartan Potassium | 45 | $743 |
| Chlorthalidone | 49 | $722 |
| Bumetanide | 23 | $626 |
| Spironolactone | 48 | $541 |
| Lisinopril | 78 | $517 |
| Amlodipine Besylate | 57 | $495 |
| Torsemide | 26 | $413 |
| Tamsulosin Hcl | 21 | $354 |
| Calcitriol | 27 | $272 |
| Furosemide | 55 | $216 |
| Allopurinol | 21 | $205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $97 | $22,65825 claims |
| BayerKerendia | $122 | $18,99219 claims |
| AstraZenecaLokelma | $236 | $4,60311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 49 nephrology providers in Delaware.
Other nephrology in Newark
- Prayus TailorNewark$127K
- William DahmsNewark$94K
- Theodore SaadNewark$26K
- Nealanjon DasNewark$6K
- Manthodi FaisalNewark$6K
- Piyaporn ApivatanagulNewark$5K
- Lindsey SlaterNewark$4K
- Christopher CanfieldNewark$3K
- Farhana ChowdhuryNewark$3K
- Carlos MachadoNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.